Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001, a Novel Anti-CD24 Antibody, at AACR 2026
Pheast Therapeutics, a clinical-stage biotechnology company advancing macrophage-directed immunotherapies for cancer, today announced that it will present three abstracts at the American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17–22 in San Diego.
Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
Pheast Therapeutics, a clinical-stage biotechnology company developing novel therapies to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PHST001 for the treatment of patients with advanced platinum-resistant ovarian cancer or in combination with chemotherapy in platinum-sensitive ovarian cancer. PHST001 is an investigational anti-CD24 monoclonal antibody designed to enhance innate immune recognition and anti-tumor activity in solid tumors.
Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors
Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced that the first patient has been treated in its Phase 1 clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumors.
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
Pheast Therapeutics, a private biotechnology company developing novel innate immune checkpoint inhibitors to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced the appointment of Raphaël Rousseau, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Rousseau brings more than 25 years of experience in oncology drug development and leadership, with extensive experience developing therapeutic antibodies, cancer vaccines, engineered T cell therapies, and small molecule inhibitors.
Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024
Pheast Therapeutics (“Pheast”), a biotech developing novel macrophage checkpoint therapies to defy cancer, today announced the presentation of new preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage "don't eat me" signal on cancer cells. The data were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place both virtually and at the George R. Brown Convention Center in Houston from November 6-10, 2024.
Pheast Unveils First Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor
Pheast Therapeutics (“Pheast”), a biotech developing novel macrophage checkpoint therapies to defy cancer, today announced the first presentation of preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells. The data to be presented at the 20th Annual PEGS Boston Summit demonstrate that PHST001 can powerfully induce an anti-cancer immune response and drive therapeutic efficacy in in vivo models.
Pheast Appoints Jacopo Leonardi as Chief Executive Officer
Pheast Therapeutics, a private biotechnology company developing novel innate immune checkpoint inhibitors to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced the appointment of Jacopo Leonardi as Chief Executive Officer. Mr. Leonardi brings more than 25 years of executive leadership spanning commercial and research and development (R&D) sectors for global pharmaceutical companies as well as experience in building new companies focused on developing novel therapeutics for high unmet medical needs.
